Angelina Jolie's case highlights the importance of knowing …
A group of more than 120 cancer researchers and physicians took…
Three scientists at universities in Pennsylvania, Illinois and …
Advertisement
FDA accepts Aveo kidney cancer pill application
Possible treatment for several cancer types
Updated: Wednesday, 28 Nov 2012, 5:04 PM EST
Published : Wednesday, 28 Nov 2012, 5:04 PM EST
CAMBRIDGE, Mass. (AP) - Aveo Oncology said Wednesday that the Food and Drug Administration will complete a review of its cancer pill Tivopath by July 28.
Aveo and its partner Astellas Pharma Inc. want to market Tivopath as a treatment for advanced kidney cancer. The companies said the FDA accepted their application, and the agency will conduct a standard 10-month review. Astellas will pay Aveo $15 million now that the filing has been accepted.
Tivopath, or tivozanib, is a tablet intended to be taken once per day. The companies are also studying the drug as a treatment for other solid tumors, including cancers of the breast and colon.
--------------------------------------------------------------------
Opinions that are derogatory, attack other users or are offensive in nature may be removed. WTHI is not responsible for the content posted in this comment section. We reserve the right to remove any offensive or off-topic remark or thread. To mark a comment for review by a moderator, click "Report Abuse."
Email This
Print This
View Story on a Single PageAdvertisement
Advertisement